摘要
目的比较非诺贝特与多烯磷脂酰胆碱治疗非酒精性脂肪肝（NAFLD）的临床疗效。方法将86例非酒精性脂肪肝患者随机分为治疗组（45例）和对照组（41例）。治疗组给予非诺贝特0．2g，每天1次，对照组给予多烯磷脂酰胆碱（易善复）456mg，每天3次，疗程均为12周。观察两组患者治疗前后的肝功能、血脂、临床症状及肝脏B超检查结果变化，比较两组的疗效。结果治疗组症状改善率、肝功能及血脂复常率、肝脏超声影像学改善明显优于对照组。治疗组与对照组有效率分别为82．2％（37／45）、63．4％（26／41），差异有统计学意义（x2=3．874，P〈0．05）。结论非诺贝特治疗非酒精性脂肪肝疗效好，且药品费用较低，无明显不良反应，值得推广应用。
Objective To investigate the clinical effects of fenofibrate and polyene phosphatidylcholine in treatment of non-alcoholic fatty liver disease. Methods 86 patients with non-alcoholic fatty liver disease were randomly divided into two groups. 45 cases in therapy group received 0.2g of fenofibrate once a day, and the others in control group received 456mg of polyene phosphatidylcholine for three times per day. All of the patients were treated for 12 weeks. Liver function, blood fat, clinical effect and liver B ultrasonic were analyzed before treatment and after 12 weeks. Results The improvement of liver function, blood fat, and liver ultrasonic imaging in therapy group was better than that in the control group. The cure rate was 82.2% in therapy group and 63.4% in control group. There was a statistical significance between the two groups （ X2 = 3. 874,P 〈 0.05）. Conclusion Fenofibrate had significant ther- apeutic effect in treatment of non-alcoholic fatty liver disease with lower costs and lower side effects.
出处
《中国基层医药》
CAS
2012年第3期325-326,共2页
Chinese Journal of Primary Medicine and Pharmacy
基金
广东省科技计划项目（200913030801319）
